Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $74.8 million.

  • Crinetics Pharmaceuticals' Non-Current Assets rose 2503.72% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $276.5 million, marking a year-over-year increase of 1395.76%. This contributed to the annual value of $59.2 million for FY2024, which is 326.14% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Non-Current Assets is $74.8 million, which was up 2503.72% from $72.3 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Assets peaked at $74.8 million during Q3 2025, and registered a low of $5.0 million during Q1 2022.
  • For the 5-year period, Crinetics Pharmaceuticals' Non-Current Assets averaged around $34.2 million, with its median value being $8.6 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 1444.31% in 2021, then soared by 90315.69% in 2023.
  • Crinetics Pharmaceuticals' Non-Current Assets (Quarter) stood at $6.3 million in 2021, then grew by 11.07% to $7.0 million in 2022, then skyrocketed by 775.29% to $61.2 million in 2023, then decreased by 3.26% to $59.2 million in 2024, then grew by 26.27% to $74.8 million in 2025.
  • Its last three reported values are $74.8 million in Q3 2025, $72.3 million for Q2 2025, and $70.3 million during Q1 2025.